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Recent advances in the field of continuous flow chemistry allow the multistep preparation of complex
molecules such as APIs (Active Pharmaceutical Ingredients) in a telescoped manner. Numerous examples
of laboratory-scale applications are described, which are pointing towards novel manufacturing pro-
cesses of pharmaceutical compounds, in accordance with recent regulatory, economical and quality guid-
ances. The chemical and technical knowledge gained during these studies is considerable; nevertheless,
connecting several individual chemical transformations and the attached analytics and purification holds
hidden traps. In this review, we summarize innovative solutions for these challenges, in order to benefit
chemists aiming to exploit flow chemistry systems for the synthesis of biologically active molecules.
 2016 Elsevier Ltd. All rights reserved.1. Introduction
The introduction of continuous processing into the manufactur-
ing of active pharmaceutical ingredients (APIs) is actively encour-
aged from regulatory agencies,1 and some of the first examples
of FDA approved, industrial production campaigns have been
recently made public.2 Furthermore, moving to continuous pro-
cesses in API production is expected to be economically benefi-
cial.3,4 However, these efforts are highly knowledge intensive5
and putting them into practice is admittedly more difficult than
in the case of batch processes.6
To date, both laboratory and industrial scale API synthesis is
conducted using classical organic synthesis methodologies, con-
sisting of a sophisticated toolbox of reaction apparatus, analytical
and work-up/purification techniques (Fig. 1a). On the other hand,
flow chemical tools also provide many possibilities,7,8 but their
implementation into multistep processes requires the design of
the system, reaction conditions, analytics, work-up and purifica-
tion processes, while constantly keeping this goal in mind (Fig. 1b).
Our ongoing efforts in this field9 inspired us to summarize the
difficulties concerning the integration of individually optimizedchemical reactions into multistep systems, as well as common
problems and their innovative solutions described in the recent lit-
erature6–8,10–18 of API continuous flow synthesis, including analyt-
ics and purification methods.2. Synthetic challenges
2.1. Choosing appropriate solvents
The outcome of the whole process and the ease of work-up and
purification can be largely influenced by the careful selection or
omission of solvents (Fig. 2).
Applying a single solvent during the whole sequence of trans-
formations reduces solvent consumption as well as the need for
evaporation.
By choosing DMF as solvent for the whole process for the syn-
thesis of condensed benzothiazoles, the three steps could be con-
tinuously coupled.9 The C-N coupling step involved in the
synthesis of Imatinib was conducted in aqueous-organic biphasic
system to prevent precipitation of inorganic byproducts, while N,
N-dimethyloctanamide cosolvent ensured efficient mass transfer
and high reaction rates. Additionally, solubility problems were pre-
vented, as each of the reagents could be dissolved in either aque-
ous or organic phase.19
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Fig. 1. Hidden traps in the realization of multistep flow synthesis of APIs.
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Neat or molten reagents led to higher reactivity and throughput in
the multistep flow chemical preparation of Ibuprofen,20,21 Rufi-
namide,22 Aliskiren,23,24 Lidocaine and Diazepam.25
Complete removal of the solvent and introduction of a different
one may be necessary in some cases, although only few continuous
examples were described for such processes. During the synthesis
of Oxomaritidine, the initially used THF had to be removed before
the last steps. The crude intermediate was re-dissolved in DCM,
which was also useful to avoid working with highly diluted mix-
tures in the final steps.26 THF was exchanged to acetonitrile usingN
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tion under the acidic conditions of the next step in course of the
synthesis of 2-aminoadamantane-2-carboxylic acid.27
Reactivity can be fine-tuned by slight modification of the sol-
vent system by addition or removal of cosolvents. During the Olan-
zapine synthesis, addition of methanol to the hitherto employed
ethyl acetate was necessary to obtain high yields in the cyclization
step leading to a thieno[1,5]-benzodiazepine intermediate.28 On
the contrary, the cosolvent had to be removed before the next step
in the modular approach towards Pregabalin, Gabapentin and
related drugs. The olefination step required small amounts of
methanol in toluene to prevent precipitation of the intermediate
phosphate salt, but methanol was not tolerated by the next
Michael addition. Aqueous in-line work-up between the steps
enabled the removal of the cosolvent.292.2. The role of (pre)mixing
Opposite to batch processing, where separately stored reagents
are introduced sequentially, the compatibility of the components
mixed together in the same stock solution and delivered by the
same pump has to be considered.
Undesired reactions in the storage flask were prevented by
introducing the base as a separate stream in a Buchwald–Hartwig
amination in the first step of the flow synthesis of Olanzapine.28 In
the synthesis of Lidocaine and Diazepam, separate pumps were
used for the neat reagent and the solvent to avoid decomposition
on standing.25
On the other hand, the preliminary deprotonation occurring in
the premixed solution of the benzimidazole substrate and the base
was found beneficial for reaching appropriate regio- and chemose-
lectivity in an alkylation leading to Telmisartan.30
When coupling the individually optimized steps during the syn-
thesis of condensed benzothiazoles, significant differences were
observed in the yields of the thiazole-formation step, depending
on the premixing time. This problem was solved by adding
reagents in two separate steps to the stream and inserting a coil
reactor for mixing.9OCH3
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In complex systems, the interaction of sub-processes has to be
taken into account during design.
Reagent systems were specifically engineered for best compat-
ibility in Bogdan’s approach to Ibuprofen (Fig. 12a). This enabled
conducting three distinct chemical steps in an uninterrupted
stream, while the excess of reagents and side products emerging
from the previous steps were tolerated in downstream reactions.20
Highly selective reactions can tolerate the presence of chemi-
cally related impurities. In the Buchwald–Hartwig amination lead-
ing to Imatinib, excess of methyl piperazine (from the previous
nucleophilic substitution) present in the reaction stream remained
inert besides the aromatic amine coupling partner, if the BrettPhos
ligand (which is selective towards primary amines) was used
(Fig. 3). This way, removing excess reagent was unnecessary.19
A complex interplay of reagents had to be managed in the pro-
cess to Rufinamide. The presence of ammonia (used in excess in
the previous amidation) resulted in the pressure dependence of
the copper catalyzed triazole synthesis, which required optimiza-
tion (Fig. 4). While bubble formation due to outgassing of ammonia
at lower pressures led to shorter residence times, at higher pres-
sures the dissolved ammonia interfered with the activity of the
copper catalyst by complex formation, causing lower yield. An
optimum of 100 psi was found with minimal gas generation, while
the catalyst remained active.31
2.4. Simplification of the process
Sophisticated synthetic procedures tend to get disproportion-
ally complex. Nevertheless, extensive optimization allowed in flow
chemistry equipment may lead to less complicated processes,
which are chemically and technologically more feasible.
In the two-step synthesis of a Mur-ligase inhibitor, the conden-
sation reaction generating imidazo bicycles was initially optimized
in the presence of catalytic amounts of p-toluenesulfonic acid
(PTSA). However, PTSA prevented the formation of the products
in the following step. The simplification of the first step by omit-
ting the acid catalyst solved this problem (Fig. 5).32
The proper design of the conditions helped avoiding a separate
quenching step in the multistep synthesis of 2-aminoadamantane-
2-carboxylic acid. The carbonyl oxide intermediate of the ozonoly-
sis was decomposed in situ, in an acetone/water solvent system,
thus the use of stoichiometric amounts of solid-supported thiourea
reagent was avoidable. Furthermore, the hydrogen-peroxide
formed as a by-product was catalytically decomposed on a man-
ganese dioxide bed in the subsequent step.27
Optimization of the heterogeneous catalyst systems allowed a
more straightforward process in the synthesis of c-nitro malo-
nates, which is closely related to the early synthetic steps of the
flow preparation of Rolipram.33 In an earlier approach, the first
step was conducted using nitromethane as a solvent (Fig. 6a).
However, the excess of nitromethane had to be removed by distil-
lation prior to the subsequent Michael addition of b-dicarbonyl
compounds, to avoid byproduct formation by further addition of
nitromethane to the b-nitrostyrene intermediate.34 Optimization
of the catalyst and conditions of the first step eliminated the need
for excess reagent (Fig. 6b), therefore the crude reaction mixture
could be directly transferred to the next reactor without interme-
diate work-up.35
2.5. Number of steps
Multistep flow chemical sequences should be designed to
employ the fewest number of chemical transformations, unit oper-
ations, reactors and pumping equipment, which helps minimizingPlease cite this article in press as: Bana P., et al. Bioorg. Med. Chem. (2017), hthe technical complexity of the system and its potential for errors
and instabilities.
As shown in the synthesis of Iloperidone, chemical transforma-
tions requiring similar conditions can be conducted in a single
reactor consecutively. This way, the ring closure and the N-alkyla-
tion could be integrated after fine-tuning of the reaction
conditions.36
The efforts towards the synthesis of Daclatasvir employed an
efficient chemical process for the formation of imidazole core
structure. Instead of the laboriously synthesized a-amido-ketones
(Fig. 7a) used in the previous approach,37 a-acyloxy-ketones
(Fig. 7b) were prepared in one step and transformed directly to
the desired cyclic product.38
The number of pumps was courageously reduced by exploiting
the convergent nature (Fig. 8) of the synthesis of Cinnarizine. Two
transformations, conducted parallel in time, both requiring addi-
tion of HCl, were carried out using a single pump. The stream
was split prior to mixing with the substrates. The same concept
was applied to the subsequent addition of NaOH. Two parallel
phase separations provided the chloro derivatives, of which
diphenylmethyl chloride was reacted with excess piperazine to
afford the monoalkylated intermediate. In the final step, two
equivalents of cinnamyl chloride were employed to yield the
desired API.39
It may occur, that increasing the number of steps is necessary,
as shown in the reaction of phenols with epichlorohydrine towards
Metoprolol and its derivatives. The base mediated alkylation
(Fig. 9a) was split into two separate steps (Fig. 9b), in case the
intermediate phenoxide was prone to precipitation.40
2.6. Compatibility of flow rates
Different types of chemical transformations can have inherently
different throughputs (Fig. 10).
In the preparation of the key intermediate of Valsartan, the first
part of the sequence required high flow rates to enable selectivity
in the preparation of the boronate intermediate through lithium
organic species.41 Then, the boronate was subjected to a Suzuki
reaction using a monolithic palladium catalyst, which in turn,
restricted the achievable flow rate. Reactor size could not be
increased in this case; consequently, the high volumetric through-
put boronate forming and the much slower flowing coupling sec-
tions of the system were connected by splitting the flow evenly
to multiple streams by an elaborate flow distributor.42
2.7. Reactor type matters
The utilization of the proper type of microreactor43 can signifi-
cantly affect the design and outcome of the reaction.
In an N-oxidation reaction during the two-step preparation of
N-nordextromethorphan conducted in a glass column filled with
sodium percarbonate, exothermic runaway leading to uncontrol-
lable pressure expansion caused the column to shatter. To over-
come this problem, a liquid-phase approach using m-
chloroperbenzoic acid as oxidant was applied. The exotherm could
be controlled due to the high surface area to volume ratio of the
flow reactor.44
The structural elements of the reactor can also affect chemical
transformations. Stainless steel tubing was replaced with commer-
cial copper tubing to catalyze the [3+2] cycloaddition step in the
synthesis of Rufinamide (Fig. 4). With this modification, both stere-
oselectivity and overall yields have improved.31
Tube-in-tube reactors based on the semipermeable Teflon
AF2400 tubing45,46 are suitable building blocks for multistep flow
processes involving gaseous reagents (Fig. 11). Precise addition of
gaseous NH3 using a tube-in-tube reactor allowed the two-stepttp://dx.doi.org/10.1016/j.bmc.2016.12.046
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Please cite this article in press as: Bana P., et al. Bioorg. Med. Chem. (2017), huninterrupted flow synthesis of Fanetizole.47 Similarly, CO2 gas
could be introduced into the stream of lithium organic intermedi-
ates, without compromising inert conditions during the continu-
ous flow preparation of Amitriptyline.48
Hazardous gases can be generated in situ using the aqueous
solutions of their precursors in a tube-in-tube device. The highly
poisonous and explosive diazomethane could be safely used in
the three-step flow process to a-halo ketone building blocks of
antiretroviral agents. The anhydrous reagent diffused through the
gas permeable inner tube and immediately reacted with the sub-
strate in the outer chamber. Any excess reagent was destroyed
before leaving the closed system to prevent human exposure.49
Owing to scalability issues, photochemical and electrochemical
transformations are rarely encountered in pharmaceutical manu-
facturing. However, miniaturization in continuous flow systems
makes photo-50–53 and electrochemical54 reactors feasible. The
synthetic pathways affordable in these systems can be involved
in novel multistep flow processes leading to pharmaceutical
compounds.
The convenient realization of a vital photochemical transforma-
tion in the semi-synthesis of Artemisinin related drugs was
enabled by the continuous approach.55–57 Using a photochemical
reactor, an unconventional route could be developed to Ibuprofen
via a photo-Favorskii rearrangement.58
Continuous flow electrochemistry was used as an enabling
technology in the synthesis of the indole alkaloid Nazlinine and
its analogues.59 In an effort to simulate cytochrome P450 oxidation
on a preparative scale, drug metabolites were produced by
microfluidic electrosynthesis. Glutathione conjugates could be
synthesized in a subsequent flow reactor, connected directly to
the output of the electrochemical flow cell.60Mur ligase inhibitor 
46% yield 
(over 2 flow steps) 
HOBt / EDC 
DIPEA 
75 °C
10 min 
st allows the uninterrupted two-step flow synthesis of a Mur ligase inhibitor. (HOBt:
: N,N-diisopropylethylamine).
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Higher productivity for bulk APIs is obtainable by robust
chemistries.
Compared to the first flow synthesis of Ibuprofen (Fig. 12a),
designed for reagent compatibility,20 the authors of the more
recent approach optimized the entire process to reach high
throughput (Fig. 12b). Although the choice of the reagents led to
high reactivity, the exothermic nature of the Friedel–Crafts reac-
tion and its quenching had to be managed. Corrosivity and clogging
issues could be mitigated by carefully choosing pumping and
quenching methods.21
Another example of improved throughput was provided in the
case of Imatinib. The first flow approach marked a milestone inPlease cite this article in press as: Bana P., et al. Bioorg. Med. Chem. (2017), hmultistep flow synthesis. This system enabled the preparation of
various derivatives, but didn’t permit large scale continuous pro-
duction.61,62 Increased productivity was achieved in a subsequent
study, by omitting solid supported reagents and intermediate in-
line purification steps in a system consisting of three continuously
operated microreactors (Fig. 3).192.9. Ensuring stability for continuous production
Continuous flow processing can only be exploited for large scale
production, if stable operation of the system can be ensured over
longer periods of time, which is often hampered by corrosion and
clogging.
Use of corrosive reagents can be prevented, by employing novel
process windows available in flow equipment, which can also
reduce the number of work-up operations. An elimination reaction,
leading to Amitriptyline proceeded at high temperature without
the use of previously employed concentrated HCl solution.48 On a
similar note, acidic conditions could be avoided in high tempera-
ture tert-butyloxycarbonyl (Boc) deprotections.63
Highly corrosive reagents may not be suitable for a standard
flow chemistry equipment and require special handling techniques
and construction materials, such as a specialized dry zone for han-
dling anhydrous HCl gas.39,64 In course of the flow syntheses of
Ibuprofen (Fig. 12), corrosion of the back pressure regulator
(BPR) unit was avoided by careful quenching of the ICl reagent.21
Hazardous leaks were encountered during an earlier study regard-
ing the same API, which could be avoided by using high perfor-
mance polymeric materials, which are resistant towards triflic
acid.20
Clogging (apart from the choice of solvent) can be prevented by
careful choice of reagents (Fig. 13). Addition of trimethylsilyl triflu-
oromethanesulfonate (TMSOTf) as Lewis acid helped to avoid the
formation of a precipitate in the hydrazone formation step in the
synthesis of the biaryl unit of Atazanavir.65 Replacing the iPrMgCl
reagent with its LiCl complex was useful in preventing clogging
in the preparation of a d-opioid receptor agonist.66
More trivially, clogging can be hindered by employing wide
bore channels or tubing, as well as applying agitation or sonic irra-
diation and controlling of fluid velocity.25,27,67 If clogging is caused
by the crystallization of low melting substances, the heating of the
problematic areas is an effective method.39 In the gas-liquid two
phase flow during an ozonolysis leading to drug candidatettp://dx.doi.org/10.1016/j.bmc.2016.12.046
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P. Bana et al. / Bioorganic & Medicinal Chemistry xxx (2017) xxx–xxx 7OZ439, the evaporation of the liquid phase caused clogging. Over-
coming this issue was possible by dilution, while flow rate was
increased in order to maintain the same level of throughput.68
2.10. Stability of packed columns
Innovative practical solutions can ensure the long term opera-
tion of packed columns, which is required for production scale
processes.
The synthesis of both enantiomers of Rolipram was realized in a
pioneering sequence consisting only of solid catalytic packed bed
reactors. In order to achieve continuous, stable operation for longer
periods of time, the catalysts were packed together with solid addi-
tives. Elaborately placed pre-columns were also introduced to the
system.69,33
In a key reduction step leading to artemisinin-derived medici-
nes, a mixture of solid NaBH4 and Celite proved to be effective.Fig. 13. Strategies for the prevention of clogging in flow steps for introducing key s
Please cite this article in press as: Bana P., et al. Bioorg. Med. Chem. (2017), hStill, LiCl and Li2CO3 additives had to be added to the reactant
bed, to prevent pressure fluctuations.57
Modification of the processing parameters may also be neces-
sary, when long term operation is desired. The opening Knoeve-
nagel addition step of the synthesis of a Nevirapine precursor
could be efficiently conducted on a solid basic Al2O3. However,
the absorption of the water formed during the reaction limited
the longevity of the catalyst. Increasing temperature and diluting
the reaction mixture proved to be beneficial for stability.702.11. Self-controlling systems and automation
The inherent instability of these increased complexity systems
can be mitigated using built-in control mechanisms and automa-
tion that are available for multistep flow systems.27,71 Such
approaches have been implemented on a system level in API syn-
theses.23–253. Analytical methods
3.1. Possibilities and limitations
Continuous flow processing allows convenient in situ analysis of
reaction mixtures, by in-line (the entire stream is passed through
the measuring cell) or on-line (representative aliquots are ana-
lyzed) techniques.7,72,73 Several different analytical systems were
used successfully, such as in-line FT-IR (predominantly with Atten-
uated Total Reflectance (ATR) cells),74–80 NIR,81,82 Raman83 and
NMR spectroscopy,84,85 as well as on-line MS86,87 and HPLC.88,89
However, everyday application of these approaches is hindered
by the fact that off-line solutions are usually more convenient,
since a wider toolbox (consisting of existing equipment) is avail-
able for the analysis of less demanding analytes (i.e. less compli-
cated matrix, solvent and concentration can be freely chosen).
Additionally, they don’t require difficult to implement sampling,
continuous dilution/concentration and automation procedures.3.2. Successful applications
Nevertheless, in-line or on-line analysis provides significant
benefits for multistep flow processing in the following situations.
In-line sensors can inform the operator about the location and
concentration of the reactants along the flow path, in order to
allow precise timing and addition of reagents in the downstream
transformations, which is extremely useful when working with
limited quantities.66,90
Instable, short-lived intermediates, such as highly reactive acyl
azide75 and diazonium86 species, as well as the VilsmeierHaack
reagent,91 can be directly studied in situ using IR spectroscopic or
mass spectrometric methods (Fig. 14). This approach providestructural elements towards Atazanavir (a), d-opioid agonist (b), and OZ439 (c).
ttp://dx.doi.org/10.1016/j.bmc.2016.12.046
Fig. 14. Selected examples of in situ analysis of reactive intermediates encountered
in continuous flow synthesis.
8 P. Bana et al. / Bioorganic & Medicinal Chemistry xxx (2017) xxx–xxxinsight into the reaction mechanism and enables more informed
optimization studies.
Automated self-optimization can be achieved by using feedback
from the output to the control the pumps and heating units, aided
by elaborate computer algorithms and DoE (Design of Experi-
ments) statistical design.78,87–89,92–94
Realization of production scale API synthesis cannot be imag-
ined without strict control of processes and final product quality.25
These efforts are exemplified by the production of Artemisinin
related APIs, where monitoring of the reaction stream after a pho-
tochemical transformation could reveal an eventual lamp failure.57
4. Purification in flow
Flow synthesis is usually followed by discontinuous purifica-
tion, because the number of available continuous solutions is lim-
ited.95 The existing methods7,73 can be classified as in-line work-up
or final product purification techniques, according to the position
in a multistep sequence, where they are preferably used.
4.1. In-line work-up
Most of the in-line work-up steps aim to remove the co-prod-
ucts, which are formed from the reagent in the course of the
planned process.6 These impurities should not be confused by
the by-products, which are structurally related to the desired pro-
duct, but their formation is the consequence of undesired side
reactions. In-line work-up can be achieved by filtration of solid
co-products, liquid-liquid phase separation, gas-liquid phase sepa-
ration or through the use of solid phase supported scavengers.
Filtration can only be categorized as a truly continuous in-line
purification method (Fig. 15), when the product remains in the
mother liquor, while the solid impurities are retained on the filter
material (and then discarded by an appropriate mechanism).27
There are several examples of extraction methods using liquid-
liquid phase separation96,97 to eliminate the excess of the
reagents,21,65 co-products,65 traces of solvents39,80 or cosolvents,29
which have been used in a previous step. Complete removal of
water may require a column filled with solid MgSO4 desiccant after
the phase separation, as exemplified in the flow preparation ofFig. 15. In-line work-up by filtration of solid co-products (BPR: back pressure
regulator).
Please cite this article in press as: Bana P., et al. Bioorg. Med. Chem. (2017), hMilnacipran analogs.80 The robust nature of liquid-liquid phase
separation allows removal of multiple impurities at the same
time.25,28,29,39,98
Insoluble gases cause irreproducible residence time (due to the
expansion of bubbles) and potential side reactions in downstream
steps. Excess of gaseous reagents or co-products can be removed
conveniently by using gas-liquid phase separation units. Hydrogen
is commonly used in flow synthesis,99,100 usually in excess
amounts. When hydrogenation is followed by other
steps,9,26,29,33,101,102 a simple buffer flask allows the outgassing of
hydrogen, after the pressure is reduced. However, in some cases
the applied chemistry did not tolerate this method. Semipermeable
Teflon AF2400 membrane (Fig. 16) was used to remove excess of
diazomethane as well as the formed nitrogen.103 A similar set-up
was employed to eliminate excess CO2 in the lithiation sequence
leading to the core of Amitriptyline.48
Columns filled with solid phase supported scavenger resins are
widely used for purification of the stream.70,104 The combination of
multiple, differently functionalized scavenger resins is a common
practice for the removal of several different impuri-
ties.44,66,33,102,105–107 In an illustrative example, removal of homo-
geneous transition metal complexes was possible this way
(Fig. 17), which prevented harmful catalytic activity in down-
stream heterogeneous nitro group reductions in the flow synthesis
of the fungicide Boscalid.104 A similar concept was applied in the
early steps towards Olanzapine.28 The drawbacks of this method
are the wide dispersion of reactants on the column90 and the
exhaustion of the resin by time, principally when the stoichiomet-
ric amounts of the immobilized reagent is consumed. These issues
can be solved by engineering solutions, such as intelligent pump-
ing90 and switching between multiple columns.108
With this knowledge at hand, multistep processes can be
designed to facilitate the purification procedure between the reac-
tion steps, which was demonstrated in the process leading to Efa-
virenz (Fig. 18). The appropriate choice of the trifluoroacetylation
reagent allowed easy removal of the co-product by a simple scav-
enging column.1094.2. Final product purification
After the final synthetic step, the API has to be purified to meet
the standards of regulatory agencies. The hitherto discussed sepa-
ration techniques, which could be ideally used between intermedi-
ate steps, are not adequate for this goal by themselves.
Continuous crystallization was employed in case of
Rufinamide22 and Aliskiren,23,24 while semi-batch recrystallization
of the crude products was necessary to provide pure
Diphenhydramine,25 Fluoxetine25 and Lidocaine.25,110 A salt
formation – neutralization sequence using multiple extraction
steps, followed by precipitation and recrystallization yielded
highly pure Diazepam.25Fig. 16. In-line work-up by gas-liquid phase separation using Teflon AF2400
membrane (BPR: back pressure regulator).
ttp://dx.doi.org/10.1016/j.bmc.2016.12.046
Fig. 17. Application of polymer bound thiourea (QuadraPureTM TU) scavenger resin
to remove homogeneous transition metal catalyst before the next catalytic step in
the flow synthesis of Boscalid.
Fig. 18. Design of the flow chemical synthetic procedure towards Efavirenz, which
facilitates in-line purification.
Fig. 19. General scheme of a continuously operated simulated moving bed (SMB)
chromatography system integrated with crystallization for the purification of
Artemisinin following its continuous flow synthesis. The circular arrow marks the
simulated counterclockwise movement of the bed (this is achieved by clockwise
switching of the inlet and outlet ports).
P. Bana et al. / Bioorganic & Medicinal Chemistry xxx (2017) xxx–xxx 9Catch and release chromatography26 enables stepwise intro-
duction of a continuous stream of the reaction mixture to a single
bed of stationary phase, followed by elution of the product. High
purity can be achieved, as it was demonstrated in case of Iloperi-
done36 and Flurbiprofen.111,112 However, the capacity of the
employed stationary phase determines the amount of the adsorbed
product during the ‘‘catch” phase and thus limits the achievable
throughput.
The complexity of artemisinin-derived medicinal compounds
call for sophisticated systems consisting of the combination of
in-line work-up and multiple final purification techniques. A
continuous three-stage purification method was developed for
a-artesunate, consisting of precipitation and filtration of
by-products, followed by chromatography in a multi-column
arrangement and finally crystallization of the product.57 In a more
recent study, a closely related system was constructed, based on
continuously operated simulated moving bed (SMB) chromatogra-
phy (Fig. 19).113,114 Following the synthesis of Artemisinin, first an
SMB chromatographic separation brought the product mixture to
92% purity, then crystallization from the concentrated mixture
provided the pure API in 99.9% purity.115Please cite this article in press as: Bana P., et al. Bioorg. Med. Chem. (2017), h5. Conclusions
The chemical knowledge and technology for the realization of
multistep flow synthesis (and the following analysis and purifica-
tion) exists, but connecting individual chemical steps holds hidden
traps. We summarized the innovative solutions for these chal-
lenges, in order to benefit chemists aiming to build such systems
for the synthesis of APIs.
The applied synthetic methods must overcome restrictions (sol-
ubility, reagent compatibility, feasibility). Still, prior design of the
complete process helps to exploit the benefits of flow methodol-
ogy. In-line or on-line analysis of reaction mixtures is well suited
for flow processing, but their real value can only be exploited for
some well-designed, special applications. The utility of the avail-
able continuous purification methods can be maximized by proper
design of the synthetic process.
The advancement of flow chemistry instrumentation is impres-
sive, and we foresee modular, customizable equipment that allow
control of the whole system through extensive standardization and
intercompatibility of the units. This would enable quick assembly
of lab-scale systems, which could be advanced for continuous API
production in the near future.
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